Sarepta Therapeutics (SRPT) Posts Q2 Loss of 85c/Share

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($0.85), which may not compare with the analyst estimate of ($0.76). Revenue for the quarter came in at $2.58 million versus the consensus estimate of $4.3 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Apollo agrees to buy EasyJet Plc. (EZJ:LN) (ESYJY); Bernstein SocGen shares investment implications
• Ategrity reports record Q2 results, names new CFO